These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 7901395

  • 1. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P, Bédard PJ, Britton DR, Kebabian JW.
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [Abstract] [Full Text] [Related]

  • 2. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys.
    Rosenzweig-Lipson S, Bergman J.
    J Pharmacol Exp Ther; 1993 Nov; 267(2):765-75. PubMed ID: 7902432
    [Abstract] [Full Text] [Related]

  • 3. Relative potency and efficacy of some dopamine agonists with varying selectivities for D1 and D2 receptors in MPTP-induced hemiparkinsonian monkeys.
    Domino EF, Sheng J.
    J Pharmacol Exp Ther; 1993 Jun; 265(3):1387-91. PubMed ID: 8099621
    [Abstract] [Full Text] [Related]

  • 4. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M, Madras BK.
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [Abstract] [Full Text] [Related]

  • 5. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 6. N-methyl-D-aspartate receptor antagonist and dopamine D1 and D2 agonist interactions in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-induced hemiparkinsonian monkeys.
    Domino EF, Sheng J.
    J Pharmacol Exp Ther; 1993 Jan; 264(1):221-5. PubMed ID: 8093726
    [Abstract] [Full Text] [Related]

  • 7. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
    Grondin R, Bédard PJ, Britton DR, Shiosaki K.
    Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
    [Abstract] [Full Text] [Related]

  • 8. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B, Bédard PJ.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [Abstract] [Full Text] [Related]

  • 9. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 10. Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates.
    Blanchet PJ, Grondin R, Bédard PJ.
    Mov Disord; 1996 Jan; 11(1):91-4. PubMed ID: 8771074
    [Abstract] [Full Text] [Related]

  • 11. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 12. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P.
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [Abstract] [Full Text] [Related]

  • 13. Role of selective D1 and D2 agonists in inducing dyskinesia in drug-naive MPTP monkeys.
    Bédard PJ, Gomez-Mancilla B, Blanchette P, Gagnon C, Falardeau P, DiPaolo T.
    Adv Neurol; 1993 Jun; 60():113-8. PubMed ID: 8093573
    [No Abstract] [Full Text] [Related]

  • 14. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Akai T, Ozawa M, Yamaguchi M, Mizuta E, Kuno S.
    J Pharmacol Exp Ther; 1995 Apr; 273(1):309-14. PubMed ID: 7714782
    [Abstract] [Full Text] [Related]

  • 15. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.
    Ryman-Rasmussen JP, Nichols DE, Mailman RB.
    Mol Pharmacol; 2005 Oct; 68(4):1039-48. PubMed ID: 15985612
    [Abstract] [Full Text] [Related]

  • 16. Influence of previous exposure to levodopa on the interaction between dizocilpine and dopamine D1 and D2 agonists in rats with 6-hydroxydopamine-induced lesions.
    Boldry RC, Chase TN, Engber TM.
    J Pharmacol Exp Ther; 1993 Dec; 267(3):1454-9. PubMed ID: 7903390
    [Abstract] [Full Text] [Related]

  • 17. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
    Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR, Piercey MF.
    J Pharmacol Exp Ther; 1995 Feb; 272(2):854-9. PubMed ID: 7853204
    [Abstract] [Full Text] [Related]

  • 18. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

  • 19. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
    Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
    [Abstract] [Full Text] [Related]

  • 20. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ, Gomez-Mancilla B, Bédard PJ.
    J Neural Transm Suppl; 1995 Jun; 45():103-12. PubMed ID: 8748615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.